Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance

BACKGROUND: Bypass activation of Src family kinases can confer resistance to EGFR tyrosine kinase inhibitors (TKIs) based on preclinical models. We prospectively assessed the safety and clinical activity of dasatinib and afatinib in combination for patients with resistant EGFR-mutant lung cancer. ME...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Cancer
Main Authors: Creelan, Ben C., Gray, Jhanelle E., Tanvetyanon, Tawee, Chiappori, Alberto A., Yoshida, Takeshi, Schell, Michael J., Antonia, Scott J., Haura, Eric B.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6474279/
https://ncbi.nlm.nih.gov/pubmed/30880334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0428-3
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker